S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
NOTICE: Your retirement is in immediate danger (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
NOTICE: Your retirement is in immediate danger (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Asian stocks mixed as Wall St inches toward bull market
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
NOTICE: Your retirement is in immediate danger (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
NOTICE: Your retirement is in immediate danger (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Asian stocks mixed as Wall St inches toward bull market
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
NOTICE: Your retirement is in immediate danger (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
NOTICE: Your retirement is in immediate danger (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Asian stocks mixed as Wall St inches toward bull market
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
NOTICE: Your retirement is in immediate danger (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
NOTICE: Your retirement is in immediate danger (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Asian stocks mixed as Wall St inches toward bull market
NASDAQ:BNTX

BioNTech (BNTX) Stock Forecast, Price & News

$109.85
+1.12 (+1.03%)
(As of 06/6/2023 ET)
Compare
Today's Range
$107.25
$110.47
50-Day Range
$102.58
$129.66
52-Week Range
$100.08
$188.99
Volume
503,487 shs
Average Volume
697,942 shs
Market Capitalization
$26.72 billion
P/E Ratio
4.22
Dividend Yield
N/A
Price Target
$171.07

BioNTech MarketRank™ Forecast

Analyst Rating
Hold
2.46 Rating Score
Upside/​Downside
55.7% Upside
$171.07 Price Target
Short Interest
Healthy
0.83% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.35mentions of BioNTech in the last 14 days
Based on 12 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
-51.29%
From $5.42 to $2.64 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.32 out of 5 stars

Medical Sector

190th out of 981 stocks

Biological Products, Except Diagnostic Industry

21st out of 152 stocks


BNTX stock logo

About BioNTech (NASDAQ:BNTX) Stock

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; Regeneron Pharmaceuticals, Inc. and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Receive BNTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioNTech and its competitors with MarketBeat's FREE daily newsletter.

BNTX Stock News Headlines

Why Shares of BioNTech Rose Friday
Lithium Has Boomed And This American Stock Is Ready..
Lithium Has Been On A Crazy Rally Over The Last 3 Year's And This Stock Could Be Next!
BioNTech SE (BNTX) Gets a Hold from Goldman Sachs
The Latest Analyst Ratings for BioNTech
The Stock That's Brining Lithium Back To America!
The American Energy Crisis Is Very Real And This Stock Is Solving That Problem On U.S Soil
BioNTech (NASDAQ:BNTX) PT Lowered to $181.00
Short Interest in BioNTech SE (NASDAQ:BNTX) Rises By 5.2%
BioNTech Se (NASDAQ: BNTX)
BioNTech (NASDAQ:BNTX) Price Target Cut to $198.00
See More Headlines

BNTX Price History

BNTX Company Calendar

Last Earnings
5/08/2023
Today
6/06/2023
Next Earnings (Estimated)
8/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BNTX
Employees
4,530
Year Founded
2008

Price Target and Rating

Average Stock Price Forecast
$171.07
High Stock Price Forecast
$260.00
Low Stock Price Forecast
$120.00
Forecasted Upside/Downside
+55.5%
Consensus Rating
Hold
Rating Score (0-4)
2.46
Research Coverage
13 Analysts

Profitability

Net Income
$9.94 billion
Pretax Margin
69.48%

Debt

Sales & Book Value

Annual Sales
$18.24 billion
Cash Flow
$42.15 per share
Book Value
$87.07 per share

Miscellaneous

Free Float
196,518,000
Market Cap
$26.75 billion
Optionable
Not Optionable
Beta
0.22

Social Links


Key Executives

  • Prof. Ugur Sahin M.D. (Age 57)
    Co-Founder, CEO & Chair of the Management Board
    Comp: $724.29k
  • Dr. Ozlem Tureci M.D. (Age 55)
    Co-Founder, Chief Medical Officer & Member of Management Board
    Comp: $717.89k
  • Prof. Christoph Hubert Huber M.D. (Age 78)
    Ph.D., Co-Founder & Member of Supervisory Board
    Comp: $62.94k
  • Mr. Jens H. Holstein (Age 59)
    CFO & Member of Management Board
    Comp: $868.29k
  • Dr. Sierk Poetting Ph.D. (Age 49)
    MD, COO & Member of Management Board
    Comp: $760.56k
  • Mr. Ryan Richardson (Age 43)
    Chief Strategy Officer, MD & Member of Management Board
    Comp: $657.09k
  • Mr. Sean Marett (Age 57)
    Chief Bus. Officer, Chief Commercial Officer & Member of Management Board
    Comp: $821.36k
  • Sylke Maas Ph.D.
    VP of Investor Relations and Bus. Strategy
  • Dr. James Timothy Patrick Ryan Ph.D.
    Sr. VP & Gen. Counsel
  • Michael Boehler
    MD & Head of Global External Communications













BNTX Stock - Frequently Asked Questions

Should I buy or sell BioNTech stock right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioNTech in the last year. There are currently 7 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BNTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BNTX, but not buy additional shares or sell existing shares.
View BNTX analyst ratings
or view top-rated stocks.

What is BioNTech's stock price forecast for 2023?

13 brokers have issued twelve-month target prices for BioNTech's stock. Their BNTX share price forecasts range from $120.00 to $260.00. On average, they anticipate the company's stock price to reach $171.07 in the next year. This suggests a possible upside of 55.7% from the stock's current price.
View analysts price targets for BNTX
or view top-rated stocks among Wall Street analysts.

How have BNTX shares performed in 2023?

BioNTech's stock was trading at $150.22 on January 1st, 2023. Since then, BNTX stock has decreased by 26.9% and is now trading at $109.85.
View the best growth stocks for 2023 here
.

Are investors shorting BioNTech?

BioNTech saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 2,020,000 shares, an increase of 5.2% from the April 30th total of 1,920,000 shares. Based on an average daily volume of 699,600 shares, the short-interest ratio is presently 2.9 days.
View BioNTech's Short Interest
.

When is BioNTech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our BNTX earnings forecast
.

How were BioNTech's earnings last quarter?

BioNTech SE (NASDAQ:BNTX) posted its quarterly earnings results on Monday, May, 8th. The company reported $2.05 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.18 by $1.87. The firm earned $1.28 billion during the quarter, compared to analysts' expectations of $1.09 billion. BioNTech had a net margin of 51.03% and a trailing twelve-month return on equity of 32.52%. BioNTech's revenue was down 80.0% compared to the same quarter last year. During the same period in the previous year, the company posted $15.98 EPS.

What is Ugur Sahin's approval rating as BioNTech's CEO?

33 employees have rated BioNTech Chief Executive Officer Ugur Sahin on Glassdoor.com. Ugur Sahin has an approval rating of 89% among the company's employees. 81.0% of employees surveyed would recommend working at BioNTech to a friend.

What other stocks do shareholders of BioNTech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioNTech investors own include Moderna (MRNA), Pfizer (PFE), Inovio Pharmaceuticals (INO), Tesla (TSLA), NVIDIA (NVDA), Novavax (NVAX), Gilead Sciences (GILD), Johnson & Johnson (JNJ), Zoom Video Communications (ZM) and Advanced Micro Devices (AMD).

When did BioNTech IPO?

(BNTX) raised $251 million in an initial public offering (IPO) on Thursday, October 10th 2019. The company issued 13,200,000 shares at $18.00-$20.00 per share. J.P. Morgan, BofA Merrill Lynch, UBS Investment Bank and SVB Leerink served as the underwriters for the IPO and Canaccord Genuity, Bryan, Garnier, Berenberg, Wolfe Capital Markets and Advisory, Kempen and Mirae Asset Securities were co-managers.

What is BioNTech's stock symbol?

BioNTech trades on the NASDAQ under the ticker symbol "BNTX."

Who are BioNTech's major shareholders?

BioNTech's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (3.10%), Flossbach Von Storch AG (1.41%), Artisan Partners Limited Partnership (1.07%), BlackRock Inc. (0.79%), Envestnet Asset Management Inc. (0.40%) and Twin Tree Management LP (0.00%).

How do I buy shares of BioNTech?

Shares of BNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioNTech's stock price today?

One share of BNTX stock can currently be purchased for approximately $109.85.

How much money does BioNTech make?

BioNTech (NASDAQ:BNTX) has a market capitalization of $26.72 billion and generates $18.24 billion in revenue each year. The company earns $9.94 billion in net income (profit) each year or $26.01 on an earnings per share basis.

How many employees does BioNTech have?

The company employs 4,530 workers across the globe.

Does BioNTech have any subsidiaries?
The following companies are subsidiares of BioNTech: Apta IT, BioNTech Austria Beteiligungen GmbH, BioNTech Business Services, BioNTech Cell & Gene Therapies, BioNTech Diagnostics, BioNTech Innovative Manufacturing Services, BioNTech Protein Therapeutics, BioNTech RNA Pharmaceuticals, BioNTech Real Estate GmbH & Co. KG, BioNTech Real Estate Verwaltungs, BioNTech Research and Development, BioNTech Small Molecules, BioNTech USA Holding, JPT, TheraCode JPT, and reBOOST Management.
Read More
How can I contact BioNTech?

BioNTech's mailing address is AN DER GOLDGRUBE 12, MAINZ 2M, 55131. The official website for the company is www.biontech.de. The company can be reached via phone at 49-61-31908-40, via email at investors@biontech.de, or via fax at 49-6131-908-4390.

This page (NASDAQ:BNTX) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -